SGL Investment Advisors’s Pfizer PFE Stock Holding History

SGL Investment Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Buy	14,975 +244	+2%	+$6.38K	0.14%	105
2026 Q1	$380K	Buy	14,731 +186	+1%	+$4.95K	0.14%	105
2025 Q4	$385K	Buy	+14,545	New	+$367K	0.15%	102

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SGL Investment Advisors's PFE Position: Q2 2026 in Review

SGL Investment Advisors increased its Pfizer (PFE) stake by 1.7% in Q2 2026, buying an estimated $6.38K and bringing the position to 14,975 shares worth $405K. The position accounts for 0.14% of the portfolio, ranked #105.

SGL Investment Advisors first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

SGL Investment Advisors held 14,975 shares of Pfizer worth $405K as of Q2 2026.
SGL Investment Advisors bought 244 Pfizer shares in Q2 2026, an estimated $6.38K.
Pfizer made up 0.14% of SGL Investment Advisors's portfolio in Q2 2026, its #105 holding.
SGL Investment Advisors first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on SGL Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.